Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFISH: Encorafenib + Cetuximab Rechallenge in BRAF V600E mCRC
NCT07178717Phase 2Not yet recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib in metastatic colorectal cancer (mCRC), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Progression-Free Survival Rate at 4 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
encorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07178717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178717.